Anika Therapeutics (ANIK) closed at $20.95 on October 30, 2026, down 3.9% from the previous close, on volume of 66,095 shares (30-day average 102,398).
Data as of October 30, 2026.
30-Oct-2026
No headlines found.
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
Globe Newswire (Thu, 22-Oct 4:01 PM ET)
Globe Newswire (Tue, 4-Aug 9:05 AM ET)
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Anika Therapeutics trades on the NASDAQ stock market under the symbol ANIK.
As of October 30, 2026, ANIK stock price declined to $20.95 with 66,095 million shares trading.
ANIK has a beta of 0.56, meaning it tends to be less sensitive to market movements. ANIK has a correlation of 0.02 to the broad based SPY ETF.
ANIK has a market cap of $280.37 million. This is considered a Small Cap stock.
Last quarter Anika Therapeutics reported $33 million in Revenue and $.42 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.43.
In the last 3 years, ANIK traded as high as $29.12 and as low as $7.87.
The top ETF exchange traded funds that ANIK belongs to (by Net Assets): VTI, IWM, DFSV, VXF, IWN.
ANIK has outperformed the market in the last year with a price return of +114.2% while the SPY ETF gained +12.3%. ANIK has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +15.9% and +4.9%, respectively, while the SPY returned +2.1% and -1.0%, respectively.
ANIK support price is $21.19 and resistance is $22.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANIK shares will trade within this expected range on the day.
